Literature DB >> 1967294

Doxorubicin decreases the repair of radiation-induced DNA damage.

J A Bonner1, T S Lawrence.   

Abstract

The mechanism that underlies doxorubicin-induced radiosensitization was investigated in a cell culture system. When V79 hamster cells were treated with doxorubicin, radiosensitization occurred as illustrated by an increase in alpha and a reduction in the mean inactivation dose (D) of the radiation survival curve. Under control conditions the radiation survival curve showed an alpha of 0.010 +/- 0.02 and a D of 4.4 +/- 0.2. After exposure to doxorubicin (1.5 micrograms/ml for 1 h prior to irradiation), alpha increased to 0.28 +/- 0.04 and D decreased to 3.0 +/- 0.3. Similar mean inactivation doses were found for doxorubicin doses of 0.75, 1.5 and 3.0 micrograms/ml, indicating that enhancement was not dose-dependent in the dose range studied. The influence of doxorubicin on radiation-induced DNA double-strand breaks (dsb) was then assessed under the same conditions as were used in the cell survival studies. Pretreatment with doxorubicin minimally affected radiation-induced dsb. However, doxorubicin increased dsb by 1.25 +/- 0.07 under conditions in which repair was allowed to proceed for 45 min. These results show that doxorubicin inhibits the repair of radiation-induced dsb. Doxorubicin is known to change DNA conformation by the stabilization of DNA topoisomerase II complexes. It is possible that these changes alter the ability of repair enzymes to recognize and correct radiation-induced damage.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967294     DOI: 10.1080/09553009014550341

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  9 in total

1.  Clinical outcome in dogs with nasal tumors treated with intensity-modulated radiation therapy.

Authors:  David W Hunley; G Neal Mauldin; Keijiro Shiomitsu; Glenna E Mauldin
Journal:  Can Vet J       Date:  2010-03       Impact factor: 1.008

2.  A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer.

Authors:  David I Rosenthal; Sue S Yom; Li Liu; Mitchell Machtay; Kenneth Algazy; Randal S Weber; Gregory S Weinstein; Ara A Chalian; Linda K Mille; Kenneth Rockwell; Margaret Tonda; Edward Schnipper; Diane Hershock
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

3.  Differential Dynamics of ATR-Mediated Checkpoint Regulators.

Authors:  Daniël O Warmerdam; Roland Kanaar; Veronique A J Smits
Journal:  J Nucleic Acids       Date:  2010-08-17

4.  Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts.

Authors:  Eirik Hagtvet; Kathrine Røe; Dag R Olsen
Journal:  Radiat Oncol       Date:  2011-10-07       Impact factor: 3.481

5.  High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours.

Authors:  M I Koukourakis; S Koukouraki; I Fezoulidis; N Kelekis; G Kyrias; S Archimandritis; N Karkavitsas
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

6.  High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles.

Authors:  Kin Man Au; Rod Balhorn; Monique C Balhorn; Steven I Park; Andrew Z Wang
Journal:  ACS Cent Sci       Date:  2018-12-26       Impact factor: 14.553

7.  Major liver resection for hepatocellular carcinoma in the morbidly obese: a proposed strategy to improve outcome.

Authors:  Omar Barakat; Mark D Skolkin; Barry D Toombs; John H Fischer; Claire F Ozaki; R Patrick Wood
Journal:  World J Surg Oncol       Date:  2008-09-10       Impact factor: 2.754

8.  Triggered radiosensitizer delivery using thermosensitive liposomes and hyperthermia improves efficacy of radiotherapy: An in vitro proof of concept study.

Authors:  Helena C Besse; Clemens Bos; Maurice M J M Zandvliet; Kim van der Wurff-Jacobs; Chrit T W Moonen; Roel Deckers
Journal:  PLoS One       Date:  2018-09-18       Impact factor: 3.240

Review 9.  Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.

Authors:  M I Koukourakis; K Romanidis; M Froudarakis; G Kyrgias; G V Koukourakis; G Retalis; N Bahlitzanakis
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.